Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
NNC0471-0119 H · 2 trials · 2 indications
Measured in milligram per kilogram (mg/kg).
| Arm | Type | Description |
|---|---|---|
| NNC0471-0119 H then Insulin Aspart | EXPERIMENTAL | Participants will receive NNC0471-0119 H subcutaneously (s.c.) in period 1 followed by insulin aspart s.c. in period 2. |
| Insulin Aspart then NNC0471-0119 H | ACTIVE_COMPARATOR | Participants will receive insulin aspart s.c. in period 1 followed by s.c. NNC0471-0119 H in period 2. |
| Name | Type | Description |
|---|---|---|
| NNC0471-0119 H | DRUG | NNC0471-0119 H will be administered subcutaneously. |
| Insulin Aspart | DRUG | Insulin aspart will be administered subcutaneously. |
Inclusion Criteria: * Male or female (sex at birth). * Age 18-69 years (both inclusive) at the time of signing the informed consent. * Diagnosed with Type 2 Diabetes (T2D) greater than or equal to (≥) 180 days before screening. * Treated with any injectable insulin, except once-weekly insulin, ≥ 18...
NNC0471-0119 H is an investigational small molecule insulin being developed for the treatment of Type 1 and Type 2 diabetes mellitus. It is administered via an insulin pump. The drug is currently in Phase 1 clinical development and is not yet approved by regulatory authorities.
NNC0471-0119 H is being developed by Novo Nordisk A/S, a pharmaceutical company listed on the stock exchange under the ticker symbol NVO. The company is conducting clinical trials to evaluate the drug's effects in participants with Type 1 and Type 2 diabetes.
NNC0471-0119 H is in Phase 1 clinical development. Two Phase 1 trials have been completed, one in Type 1 diabetes and one in Type 2 diabetes. The drug is investigational and has not received FDA approval.
NNC0471-0119 H has been studied in two completed Phase 1 trials. NCT06809621 tested the drug in 43 participants with Type 1 diabetes in Germany. NCT07068295 tested it in 65 participants with Type 2 diabetes in Germany. Both trials evaluated the drug when given by an insulin pump.
NNC0471-0119 H is an insulin analog designed to regulate blood glucose levels in people with diabetes. As a small molecule insulin, it is intended to be delivered continuously via an insulin pump to mimic the body's natural insulin secretion and control blood sugar.